Ridgeline Therapeutics is a Houston-based biotechnology company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse Type 2 diabetes, obesity, muscular dystrophies, and sarcopenia (age-related muscle degeneration).
Diabetes & NASH. We have developed novel oral drugs that treat the root cause, not simply the symptoms, of Type 2 diabetes (T2D) and obesity-linked NASH. Our drugs directly shrink excess fat deposits, resulting in long-term improvements in insulin sensitivity and normalized circulating glucose levels in individuals battling T2D. Significant reductions in hepatic lipid accumulation in observed in obese animals, indicating these drugs can prevent or reverse fatty liver disease and the progression to non-alcoholic steatohepatitis (NASH).
Sarcopenia. There are no approved drug treatments to prevent, slow, or reverse sarcopenia, the age-related degenerative loss of skeletal muscle and tissue quality which associate with progressive and significant decreases in muscle strength, function, and regenerative ability. We are developing small molecule drug candidates that rejuvenate muscle stem cells in aged populations and offer an innovative approach to treat sarcopenia. Prophylactic use of these drugs is expected to significantly delay the onset and reduce the severity of sarcopenia, leading to greatly enriched lives for older adults.
Muscular dystrophies. We are developing novel orally-bioavailable drugs that improve muscle function, prevent muscle stem cell senescence, and activate muscle stem cells. These drugs prevent the progressive skeletal muscle weakness and degeneration that is a hallmark of chronic muscular dystrophies (e.g., Duchene, Becker, Limb-girdle, Miyoshi muscular dystrophies, Pompe disease).